Unicycive Therapeutics Reports $12.8 Million Net Loss and Increased Cash Reserves for Q1 2026

Unicycive Therapeutics, Inc. reported a significant net loss of $12.8 million for the three months ended March 31, 2026, compared to a net income of $570,000 for the same period in 2025. The company's total operating expenses increased by 6% to $8.4 million, driven primarily by a 17% rise in general and administrative expenses, which reached $6.8 million. Research and development expenses decreased by 26% to $1.6 million, reflecting a reduction in drug development costs. The company’s accumulated deficit grew to $140.6 million as of March 31, 2026, up from $127.8 million at the end of the previous fiscal year.

In terms of liquidity, Unicycive's cash and cash equivalents increased to $37.4 million as of March 31, 2026, up from $29.2 million at the end of 2025. The company raised approximately $19.6 million during the first quarter of 2026 through the sale of 3,123,537 shares of common stock under a sales agreement with Guggenheim Securities, LLC. This capital is intended to support ongoing clinical trials and operational expenses as the company advances its product candidates, including oxylanthanum carbonate and UNI-494.

Strategically, Unicycive has made notable progress in its product development pipeline. The company resubmitted its New Drug Application (NDA) for oxylanthanum carbonate to the FDA in December 2025, following a Type A meeting that addressed a previously identified deficiency. The FDA accepted the resubmission, setting a target action date of June 29, 2026. Additionally, the company continues to explore partnerships and licensing opportunities to expand its market reach, particularly in the renal disease sector.

Operationally, Unicycive has seen fluctuations in its engagement metrics, with a notable increase in the number of shares outstanding, which rose from approximately 22.1 million at the end of 2025 to about 25.2 million by March 31, 2026. The company’s employee headcount has also likely increased as it continues to build its team to support its clinical and commercial efforts. However, the company remains cautious about its future funding requirements, indicating that it may need to raise additional capital to sustain its operations and support ongoing development initiatives.

Looking ahead, Unicycive anticipates continued operating losses as it invests in the development of its product candidates. The company is focused on securing additional financing through equity offerings, collaborations, or other means to ensure it can meet its operational needs and advance its clinical programs. Management believes that, based on current expenditures, the company has sufficient resources to continue operations for at least the next year, but acknowledges the inherent uncertainties in the biotechnology sector that could impact its financial position and operational plans.